Evidence map›Paper›PMID 29073169›Full record

ArticlePloS one2017

Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer.

Charles Johannessen, Line Moi, Yury Kiselev, Mona Irene Pedersen, Stig Manfred Dalen, Tonje Braaten, Lill-Tove Busund

Abstract readValidation Study
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. The prognostic value of microRNA-biogenesis genesAmerican journal of translational research · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Charles JohannessenDepartment of Medical Biology, UiT-The Arctic University of Norway, Tromsø, Norway.ORCID http://orcid.org/0000-0002-0459-6468
Line MoiDepartment of Medical Biology, UiT-The Arctic University of Norway, Tromsø, Norway.
Yury KiselevDepartment of Life Sciences and Health, Oslo and Akershus University College of Applied Sciences, Oslo, Norway.
Mona Irene PedersenDepartment of Clinical Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Stig Manfred DalenDepartment of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.
Tonje BraatenDepartment of Community Medicine, UiT-The Arctic University of Norway, Tromsø, Norway.
Lill-Tove BusundDepartment of Medical Biology, UiT-The Arctic University of Norway, Tromsø, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional regulators of gene expression and are dysregulated in cancer. Studies of miRNAs to explore their potential as diagnostic and prognostic markers are of great scientific interest. Here, we investigate the functional properties and expression of the miR-143/145 cluster in breast cancer (BC) in vitro and in vivo. The ER positive MCF7, the HER2 positive SK-BR-3, and the triple negative cell line MDA-MB-231 were used to assess cell proliferation and cell invasion. Expression of miRNA in 108 breast cancers in the Norwegian Women and Cancer Study and 44 benign tissue controls were analyzed by microarray and validated by RT-PCR. Further, in situ hybridization (ISH) was used to study the cellular and subcellular distribution of the miRNAs. In vitro, miR-143 promoted proliferation of MCF7 and MDA-MB-231 cells, whereas miR-145 and the cotransfection of both miRNAs inhibited proliferation in all three cell lines. The cells' invasive capacity was reduced after transfection and cotransfection of the miRNAs. In line with the tumor suppressive functions in vitro, the expression of miR-143 and miR-145 was lower in malignant compared to benign breast tissue, and lower in the more aggressive tumors with higher tumor grade, loss of ER and the basal-like phenotype. ISH revealed miR-143 to be cytoplasmatic and predominantly expressed in luminal cells in benign tissue, whilst miR-145 was nuclear and with strong staining in myoepithelial cells. Both miRNAs were present in malignant epithelial cells and stromal fibroblasts in BC. This study demonstrates that miR-143 and -145 have functional properties and expression patterns typical for tumor suppressors, but the function is influenced by cellular factors such as cell type and miRNA cotransfection. Further, the nuclear functions of miR-145 should be explored for a more complete understanding of the complexity of miRNA regulation and function in BC.

Indexed as

Breast NeoplasmsCell Line, TumorFemaleHumansIn Situ HybridizationMicroRNAsMultigene FamilyOligonucleotide Array Sequence AnalysisMicroRNAsMIRN143 microRNA, humanMIRN145 microRNA, human

Identifiers

PMID29073169
PMCPMC5657998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.